Fortgeschrittenes Nierenzellkarzinom: Nivolumab/Cabozantinib versus Sunitinib
- PMID: 35078256
- DOI: 10.1055/a-1559-4893
Fortgeschrittenes Nierenzellkarzinom: Nivolumab/Cabozantinib versus Sunitinib
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Comment on
-
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
